Completed PHASE1 INTERVENTIONAL 3-arm NCT03030430

Study of Bevacizumab(BAT1706) and Comparators in Healthy Subjects

Randomized, Double-blind, Single-dose, 3-arm Parallel Design Comparative Pharmacokinetic(PK) and Safety Study of BAT1706 Versus European Union(EU)-Sourced Avastin® and United State (US)-Sourced Avastin® Administered in Healthy Subjects

Sponsor: Bio-Thera Solutions

Conditions NSCLC

Interventions BAT1706 injection EU-sourced Avastin US-sourced Avastin

Updated 6 times since 2017 Last updated: Jul 27, 2018 Started: Mar 15, 2016 Primary completion: May 16, 2017 Completion: Jun 28, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on NSCLC, this trial is completed. The trial is conducted by Bio-Thera Solutions and has accumulated 6 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Aug 2018 — Jan 2021 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Jun 2018 — Aug 2018 [monthly]

Recruiting PHASE1

▶ Show 1 earlier version

Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bio-Thera Solutions

Data source: Bio-Thera Solutions

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Christchurch, New Zealand